Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in PCa

Updated: Jul 7, 2020

Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study

Authors: Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K


Background: The impact of treatment delays on prostate cancer–specific outcomes remains ill-defined. This study investigates the effect of time to treatment on biochemical disease control after prostatectomy.

Methods: This retrospective study includes 1,807 patients who received a prostatectomy as a primary treatment at two large tertiary referral centers from 1987 to 2015. Multivariate cox model with restricted cubic spline was used to identify optimal time to receive treatment and estimate the risk of biochemical recurrence.

Results: Median follow-up time of the study was 46 (interquartile range, 18–86) months. Time to treatment was subcategorized based on multivariate cubic spline cox model. In multivariate spline model, adjusted for all the pertinent pretreatment variables, inflection point in the risk of biochemical recurrence was observed around 3 months, which further increased after 6 months. Based on spline model, time to treatment was then divided into 0 to 3 months (61.5%), >3 to 6 months (31.1%), and 6 months (7.4%). In the adjusted cox model, initial delays up to 6 months did not adversely affect the outcome; however, time to treatment >6 months had significantly higher risk of biochemical recurrence (HR, 1.84; 95% confidence interval, 1.30–2.60; P < 0.01).

Conclusions: The initial delays up to 6 months in prostate cancer primary treatment may be sustainable without adversely affecting the outcome. However, significant delays beyond 6 months can unfavorably affect biochemical disease control.

Impact: Time to treatment can aid clinicians in the decision-making of prostate cancer treatment recommendation and educate patients against unintentional treatment delays.


Full journal: https://cebp.aacrjournals.org/content/28/3/570

0 views0 comments

Recent Posts

See All

Sequence three million genomes across Africa

Ambroise Wonkam COMMENT 10 FEBRUARY 2021 Capture the full scope of variation to improve health care, equity and medical research globally. PDF version Two decades after the completion of the Human Gen

MADCaP Network
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215

Supported by Dana-Farber Cancer Institute

MADCaP is grant-funded by the National Cancer Institute

© Copyright 2016-2020 

Dana-Farber Cancer Institute.

Use of MADCaP is subject to our terms of use and our privacy policy.

NCI_Stacked_COLOR.png
img-logo-2x-new.png